Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group

Richard van der Jagt, K. Sue Robinson, Andrew Belch, Elizabeth Yetisir, George Wells, Loree Larratt, Chaim Shustik, Stefan Gluck, Alexander Keith Stewart, David Sheridan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose. The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML). The combinations of idarubicin 12 mg/m2/d on days 1 - 3 and Ara-C (200 mg/ m2/d) on days 1 - 7 (IDAC) followed by mitoxantrone 10 mg/ m2/day, and etoposide 100 mg/m2/day, on days 1 - 5 (NOVE) were used according to patient response to induction and consolidation. Patients and methods. In this multi-centre open-label phase II study, 140 patients up to age 80 were given induction with IDAC. Patients were entered between March 1993 and August 1995. If patients had persistent blasts at day 14 or on recovery, they were given NOVE. As consolidation, patients achieving complete remission (CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE. Patients achieving CR after NOVE were given 2 further cycles of NOVE. Results. 76% of all patients achieved remission after IDAC +/- NOVE, 81% in patients aged ≤60 years and 67% in patients aged >60. Overall, induction mortality was 11% and toxicity was similar to other cooperative group studies. Median follow-up was 104.0 months with 95% CI: (100.0, 105.2). Median overall survival (OS) in responding patients ≤60 was not reached: Of the 79 responders ≤60, 35 died. The median disease free survival (DFS) in these responding patients was 22.7 (14.9, na) months. Median OS and DFS in responding patients >60 was 10.0 (7.3, 15.2) months and 7.5 (6.2, 15.2) months, respectively. Conclusion. The results of this trial are very encouraging and suggest that there may be long-term benefit to this method. On the basis of these results, a randomized phase III trial has been performed.

Original languageEnglish (US)
Pages (from-to)697-706
Number of pages10
JournalLeukemia and Lymphoma
Volume47
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Idarubicin
Mitoxantrone
Cytarabine
Etoposide
Acute Myeloid Leukemia
Leukemia
Disease-Free Survival
Survival

Keywords

  • Acute myeloid leukemia
  • Adult leukemia
  • Long-term follow-up
  • Non-cross resistant
  • Response-adapted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia : 10 year follow-up of a study by the Canadian Leukemia Studies Group. / van der Jagt, Richard; Robinson, K. Sue; Belch, Andrew; Yetisir, Elizabeth; Wells, George; Larratt, Loree; Shustik, Chaim; Gluck, Stefan; Stewart, Alexander Keith; Sheridan, David.

In: Leukemia and Lymphoma, Vol. 47, No. 4, 04.2006, p. 697-706.

Research output: Contribution to journalArticle

van der Jagt, Richard ; Robinson, K. Sue ; Belch, Andrew ; Yetisir, Elizabeth ; Wells, George ; Larratt, Loree ; Shustik, Chaim ; Gluck, Stefan ; Stewart, Alexander Keith ; Sheridan, David. / Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia : 10 year follow-up of a study by the Canadian Leukemia Studies Group. In: Leukemia and Lymphoma. 2006 ; Vol. 47, No. 4. pp. 697-706.
@article{8fd9c7607f764386a792731111253660,
title = "Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group",
abstract = "Purpose. The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML). The combinations of idarubicin 12 mg/m2/d on days 1 - 3 and Ara-C (200 mg/ m2/d) on days 1 - 7 (IDAC) followed by mitoxantrone 10 mg/ m2/day, and etoposide 100 mg/m2/day, on days 1 - 5 (NOVE) were used according to patient response to induction and consolidation. Patients and methods. In this multi-centre open-label phase II study, 140 patients up to age 80 were given induction with IDAC. Patients were entered between March 1993 and August 1995. If patients had persistent blasts at day 14 or on recovery, they were given NOVE. As consolidation, patients achieving complete remission (CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE. Patients achieving CR after NOVE were given 2 further cycles of NOVE. Results. 76{\%} of all patients achieved remission after IDAC +/- NOVE, 81{\%} in patients aged ≤60 years and 67{\%} in patients aged >60. Overall, induction mortality was 11{\%} and toxicity was similar to other cooperative group studies. Median follow-up was 104.0 months with 95{\%} CI: (100.0, 105.2). Median overall survival (OS) in responding patients ≤60 was not reached: Of the 79 responders ≤60, 35 died. The median disease free survival (DFS) in these responding patients was 22.7 (14.9, na) months. Median OS and DFS in responding patients >60 was 10.0 (7.3, 15.2) months and 7.5 (6.2, 15.2) months, respectively. Conclusion. The results of this trial are very encouraging and suggest that there may be long-term benefit to this method. On the basis of these results, a randomized phase III trial has been performed.",
keywords = "Acute myeloid leukemia, Adult leukemia, Long-term follow-up, Non-cross resistant, Response-adapted therapy",
author = "{van der Jagt}, Richard and Robinson, {K. Sue} and Andrew Belch and Elizabeth Yetisir and George Wells and Loree Larratt and Chaim Shustik and Stefan Gluck and Stewart, {Alexander Keith} and David Sheridan",
year = "2006",
month = "4",
doi = "10.1080/10428190500467917",
language = "English (US)",
volume = "47",
pages = "697--706",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia

T2 - 10 year follow-up of a study by the Canadian Leukemia Studies Group

AU - van der Jagt, Richard

AU - Robinson, K. Sue

AU - Belch, Andrew

AU - Yetisir, Elizabeth

AU - Wells, George

AU - Larratt, Loree

AU - Shustik, Chaim

AU - Gluck, Stefan

AU - Stewart, Alexander Keith

AU - Sheridan, David

PY - 2006/4

Y1 - 2006/4

N2 - Purpose. The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML). The combinations of idarubicin 12 mg/m2/d on days 1 - 3 and Ara-C (200 mg/ m2/d) on days 1 - 7 (IDAC) followed by mitoxantrone 10 mg/ m2/day, and etoposide 100 mg/m2/day, on days 1 - 5 (NOVE) were used according to patient response to induction and consolidation. Patients and methods. In this multi-centre open-label phase II study, 140 patients up to age 80 were given induction with IDAC. Patients were entered between March 1993 and August 1995. If patients had persistent blasts at day 14 or on recovery, they were given NOVE. As consolidation, patients achieving complete remission (CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE. Patients achieving CR after NOVE were given 2 further cycles of NOVE. Results. 76% of all patients achieved remission after IDAC +/- NOVE, 81% in patients aged ≤60 years and 67% in patients aged >60. Overall, induction mortality was 11% and toxicity was similar to other cooperative group studies. Median follow-up was 104.0 months with 95% CI: (100.0, 105.2). Median overall survival (OS) in responding patients ≤60 was not reached: Of the 79 responders ≤60, 35 died. The median disease free survival (DFS) in these responding patients was 22.7 (14.9, na) months. Median OS and DFS in responding patients >60 was 10.0 (7.3, 15.2) months and 7.5 (6.2, 15.2) months, respectively. Conclusion. The results of this trial are very encouraging and suggest that there may be long-term benefit to this method. On the basis of these results, a randomized phase III trial has been performed.

AB - Purpose. The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML). The combinations of idarubicin 12 mg/m2/d on days 1 - 3 and Ara-C (200 mg/ m2/d) on days 1 - 7 (IDAC) followed by mitoxantrone 10 mg/ m2/day, and etoposide 100 mg/m2/day, on days 1 - 5 (NOVE) were used according to patient response to induction and consolidation. Patients and methods. In this multi-centre open-label phase II study, 140 patients up to age 80 were given induction with IDAC. Patients were entered between March 1993 and August 1995. If patients had persistent blasts at day 14 or on recovery, they were given NOVE. As consolidation, patients achieving complete remission (CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE. Patients achieving CR after NOVE were given 2 further cycles of NOVE. Results. 76% of all patients achieved remission after IDAC +/- NOVE, 81% in patients aged ≤60 years and 67% in patients aged >60. Overall, induction mortality was 11% and toxicity was similar to other cooperative group studies. Median follow-up was 104.0 months with 95% CI: (100.0, 105.2). Median overall survival (OS) in responding patients ≤60 was not reached: Of the 79 responders ≤60, 35 died. The median disease free survival (DFS) in these responding patients was 22.7 (14.9, na) months. Median OS and DFS in responding patients >60 was 10.0 (7.3, 15.2) months and 7.5 (6.2, 15.2) months, respectively. Conclusion. The results of this trial are very encouraging and suggest that there may be long-term benefit to this method. On the basis of these results, a randomized phase III trial has been performed.

KW - Acute myeloid leukemia

KW - Adult leukemia

KW - Long-term follow-up

KW - Non-cross resistant

KW - Response-adapted therapy

UR - http://www.scopus.com/inward/record.url?scp=33646803000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646803000&partnerID=8YFLogxK

U2 - 10.1080/10428190500467917

DO - 10.1080/10428190500467917

M3 - Article

C2 - 16690529

AN - SCOPUS:33646803000

VL - 47

SP - 697

EP - 706

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -